Biofil Chemicals & Pharmaceuticals Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Biofil Chemicals & Pharmaceuticals (NSE: BIOFIL) Q4 FY26 results are scheduled for May 15, 2026. Trading at Rs 48 as of April 2026 — down -42% from its 52-week high of Rs 82 — the stock has been on investors’ watchlist ahead of what could be a pivotal quarterly result. This article covers the confirmed results date, analyst consensus estimates, five performance factors, five risks, analyst ratings, and share price outlook for Biofil Chemicals & Pharmaceuticals.

Q4 (January-March 2026) is the year’s final quarter, bringing full-year FY26 results, management’s FY27 guidance, and the final dividend recommendation — all from a single board meeting on May 15, 2026.

Get free investment predictions from SEBI-registered analysts on Univest.

Biofil Chemicals & Pharmaceuticals Q4 Results 2026 Date

Biofil Chemicals & Pharmaceuticals Q4 FY26 results date is May 15, 2026.

Why Q4 FY26 Matters

Q4 FY26 is the final quarter of FY2025-26. Biofil Chemicals & Pharmaceuticals’s board on May 15, 2026 will approve the full-year FY26 results, consider a final dividend recommendation, and provide the first formal commentary on FY27 business outlook — making this the single most important results event of the year.

Biofil Chemicals & Pharmaceuticals Q4 FY26 Earnings Estimates

Access premium research on Univest.

Screen Biofil Chemicals & Pharmaceuticals live on the Univest Screener. Download the Univest iOS App or Univest Android App for real-time Q4 result alerts.

5 Key Factors Driving Biofil Chemicals & Pharmaceuticals Q4 FY26 Performance

1. Pharmaceutical Ingredient Supply

Biofil Chemicals manufactures pharmaceutical intermediates for domestic formulators.

2. Quality Compliance

GMP compliance determines market access for pharma ingredient manufacturers.

3. API Demand Recovery

Recovery in API demand as global pharmaceutical destocking normalises.

4. Cost Competitive Manufacturing

Manufacturing cost competitiveness determines order wins from formulation customers.

5. Expansion of Product Portfolio

Adding new pharma intermediate products expands customer base.

5 Risks to Watch in Biofil Chemicals & Pharmaceuticals Q4 FY26

Risk 1: Pharma Ingredients Sector Risk

Sector headwinds including input cost pressure, demand cyclicality, and competition could impact Q4 performance.

Risk 2: Revenue Concentration

Customer or geographic concentration creates variance risk.

Risk 3: Regulatory Environment

Policy and regulatory changes in the sector can create compliance or revenue risks.

Risk 4: Working Capital Management

Efficient working capital management determines free cash flow quality in Q4.

Risk 5: Macroeconomic Sensitivity

Global and domestic macroeconomic conditions affect end-market demand.

Biofil Chemicals & Pharmaceuticals Share Price and Analyst Ratings

Conclusion

Biofil Chemicals & Pharmaceuticals Q4 FY26 results on May 15, 2026 will reflect Pharma Ingredients sector performance in the January-March 2026 quarter. Revenue above Rs 85 Cr with EBITDA 8% would constitute a beat. The +10% revenue YoY trajectory and management FY27 guidance are the primary catalysts for re-rating. At Rs 48 — down -42% from its 52-week high of Rs 82 — the stock offers a more reasonable entry point than earlier in the year.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Biofil Chemicals & Pharmaceuticals Q4 results 2026 date?

Biofil Chemicals & Pharmaceuticals Q4 FY26 results date is May 15, 2026. The board of directors will approve the quarter and full-year FY26 results and consider recommending a final dividend for FY26 shareholders.

Q: What is Biofil Chemicals & Pharmaceuticals Q4 FY26 revenue estimate?

Analyst consensus estimate for Biofil Chemicals & Pharmaceuticals Q4 FY26 revenue is Rs 85 Cr. Q3 FY26 actual revenue was Rs 77 Cr. Actual Q4 results may differ based on operating conditions.

Q: What is Biofil Chemicals & Pharmaceuticals Q4 FY26 PAT estimate?

Analyst consensus estimate for Biofil Chemicals & Pharmaceuticals Q4 FY26 net profit (PAT) is Rs 4 Cr. Q3 FY26 actual PAT was Rs 3.5 Cr.

Q: Will Biofil Chemicals & Pharmaceuticals declare a dividend in Q4 FY26?

Biofil Chemicals & Pharmaceuticals is expected to declare Rs 0.10 for FY26, subject to board approval on May 15, 2026 and shareholder approval at the AGM.

Q: What is Biofil Chemicals & Pharmaceuticals’s current share price?

Biofil Chemicals & Pharmaceuticals is trading at Rs 48 as of April 2026, with a 52-week range of Rs 38 to Rs 82. The 1-year return is -42%.

Q: What were Biofil Chemicals & Pharmaceuticals Q3 FY26 results?

In Q3 FY26, Biofil Chemicals & Pharmaceuticals reported revenue of Rs 77 Cr and PAT of Rs 3.5 Cr. Q4 FY26 on May 15, 2026 provides the year-end comparison.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered on Univest Blogs.

Q: Is Biofil Chemicals & Pharmaceuticals a good investment ahead of Q4 results?

This article does not constitute investment advice. Biofil Chemicals & Pharmaceuticals trades at Rs 48 — down -42% from its peak. Consult a SEBI-registered advisor before investing.

Recent Article

Balkrishna Industries Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balkrishna Paper Mills Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balaji Telefilms Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balaji Amines Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook